2023-07-16-世界卫生组织-Immunization_Lesotho_2023_country_profile_30页_412kb

Lesotho Immunization Coverage (WHO/UNICEF 2022)

This document summarizes country-specific immunization coverage estimates (BCG, DTP1/DTP3/Pol3/HiB/HepB/RCV/PCV/IPV, MCV1/MCV2/Rabies/YFV) for children under one year, primarily sourced from national reports, surveys, and administrative data between 2011-2022, representing a revision scheduled for the next 30 days.

Findings:

• Data & Method: Estimates vary in quality. Default methods combine national data calibrated by UN PD/WHO, surveys, and administrative data. Quality is graded (GoC: •++, •+, •, •-, ---), with most grades indicating high fluctuations or data point issues.
• System Stability: National administrative data often shows yearly volatility (e.g., BCG, MCV1, DTP, MCV covers), leading to frequent resort to earlier years (like 2018) or surrogate measures (surveys). Recommended actions include independent assessments to verify recent estimates.
• System Challenges: Frequent national or routine level stockouts (e.g., BCG, DTP, MCV, HepB) impact coverage and suggest systemic issues in recording/monitoring. National-level recording systems are identified as problematic.
• Recent Stability: Some estimates show consistency (e.g., around 87% for DTP3 and Pol3 between 2018-2022).
• Survey Data: Surveys provide alternative data at specific points. For instance:
  • 2018 Multiple Indicator Cluster Survey: DTP1/3/BCG≈87-90%, MCV1≈87%, Pol3≈87-90%, HepB3≈83%. Less used due to volatility.
  • 2016 Lesotho Multiple Indicator Cluster Survey: DTP3≈89%, HiB≈92%, PCV2≈67%, HepB3 approx. 79%. Used to support earlier estimates.
  • 2014 Lesotho Demographic and Health Survey: DTP1/3, MCV1 around 93%, HiB, PCV up to 98%. Used to support estimates.
  • 2003 Lesotho EMICS Draft Preliminary Report: DTP1/3, Pol1, etc., mid-80s/90s.
• Notable Improvements/Less Data: HepBB/HepB3 data began appearing longer late; RCV1 estimates directly derived from MCV1.

In summary, Lesotho's immunization system has shown general coverage levels above 70%+ for many key indicators recently (especially DTP3, Pol3, BCG, MCV1/2), but faces intermittent challenges due to reporting and recording system inconsistencies and periodic stockouts.